Drug Delivery News and Research RSS Feed - Drug Delivery News and Research

Drug delivery is a term that refers to the delivery of a pharmaceutical compound into the body. Most common methods of delivery include the preferred non-invasive oral (through the mouth), nasal, pneumonial (inhalation), and rectal routes. Much research is now focussing on nanotechnology as a drug delivery method.
Bio Light's IOPtiMate system approved in Canada for treatment of glaucoma

Bio Light's IOPtiMate system approved in Canada for treatment of glaucoma

Bio Light Israeli Life Sciences Investments Ltd., an emerging global ophthalmic company focused on the discovery, development and commercialization of products and product candidates which address ophthalmic conditions, announced today that its IOPtiMate system for the treatment of glaucoma has been approved by the Canadian Medical Devices Bureau, allowing the Company to commercialize the surgical system in Canada. [More]
Halozyme Therapeutics, Lilly sign global collaboration and license agreement

Halozyme Therapeutics, Lilly sign global collaboration and license agreement

Halozyme Therapeutics, Inc. today announced a global collaboration and license agreement with Eli Lilly and Company to develop and commercialize products combining proprietary Lilly compounds with Halozyme's ENHANZE platform. [More]
Research project explores use of nanoparticles as a way to disinfect wounds

Research project explores use of nanoparticles as a way to disinfect wounds

Infections contracted during surgical operations are a serious healthcare problem, leading to death in some cases. Now, a research project at the University of Huddersfield is investigating the use of nanoparticles as a way to disinfect wounds. It could prove to be much more effective than existing techniques because the particles would be tiny enough to enter the skin via hair follicles, ensuring much better penetration of the area affected by surgery. [More]
Tris announces FDA approval of first-ever ER chewable tablet

Tris announces FDA approval of first-ever ER chewable tablet

Tris Pharma, Inc. is pleased to announce that the U.S. Food and Drug Administration approved the first-ever extended-release (ER) chewable tablet, capping off a highly productive year with three Tris-developed NDAs approved in a calendar year. [More]
New rapid test can detect malaria parasites, viruses and biomarkers

New rapid test can detect malaria parasites, viruses and biomarkers

Nothing could be simpler: a drop of blood is placed on a special carrier substance; after a wait of a few minutes, the slide is placed on a device that emits polarised light thanks to an inexpensive polarisation filter. It is covered with a lid containing a second polarisation filter, which blocks the light from all materials except crystalline or materials with directional properties. [More]
BD announces launch of BD FACSCelesta flow cytometer during ASCB annual meeting

BD announces launch of BD FACSCelesta flow cytometer during ASCB annual meeting

BD (Becton, Dickinson and Company), a leading global medical technology company, today announced the launch of the BD FACSCelesta flow cytometer during the 2015 American Society for Cell Biology annual meeting. Uniquely designed to leverage the broad BD Horizon Brilliant reagent portfolio, this new system offers simultaneous measurement of up to 14 different single cell characteristics. [More]
CareFusion obtains two FDA clearances for spine augmentation devices

CareFusion obtains two FDA clearances for spine augmentation devices

CareFusion, a BD company, today announced the U.S. Food and Drug Administration has cleared two 510(k)s for its spine augmentation devices. [More]
New three-drug delivery system shows promise for treatment of metastatic melanoma

New three-drug delivery system shows promise for treatment of metastatic melanoma

Researchers have developed a new three-drug delivery system for cancer treatment, especially metastatic melanoma, the deadliest form of skin cancer - and shown that the system may have particular value with cancers like this that often spread through the lymphatic system. [More]
BioLight announces first sale of IOPtiMate system in Portugal

BioLight announces first sale of IOPtiMate system in Portugal

BioLight Life Sciences Investments Ltd., a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, today announced the first sale of the IOPtiMate system to a medical center located in Portugal. [More]
Researchers reveal potential for exploring new treatment options for triple-negative breast cancer

Researchers reveal potential for exploring new treatment options for triple-negative breast cancer

Researchers from Caris Life Sciences and Fox Chase Cancer Center – Temple Health announced the presentation of two studies revealing the potential for exploring new therapeutic options for triple-negative breast cancer (TNBC) at the 2015 San Antonio Breast Cancer Symposium. [More]
BioLight signs joint financing agreement with two Asia-based venture capital firms

BioLight signs joint financing agreement with two Asia-based venture capital firms

BioLight Life Sciences Investments, a company focused primarily on the discovery, development and commercialization of breakthrough ophthalmic diagnostics and therapeutics, announced today that it has entered into a joint financing agreement (the "Agreement") with two Asia-based venture capital firms (the "New Investors"), pursuant to which BioLight and the New Investors will make a direct equity investment in BioLight's IOPtima Ltd. subsidiary via a private placement. [More]
Impax's NUMIENT granted EC marketing authorization for symptomatic treatment of adult patients with Parkinson's disease

Impax's NUMIENT granted EC marketing authorization for symptomatic treatment of adult patients with Parkinson's disease

Impax Laboratories, Inc. today announced that the European Commission has granted marketing authorization for NUMIENT (Levodopa and Carbidopa), a modified-release oral capsule formulation for the symptomatic treatment of adult patients with Parkinson's disease. [More]
UF Health researcher finds simple way to treat immune-related disorder in mice

UF Health researcher finds simple way to treat immune-related disorder in mice

A University of Florida Health researcher has found a simple, rapid way to treat an immune-related disorder in mice, an approach that could eventually help multiple sclerosis patients after further research. [More]
New collaboration aims to develop novel generation artificial pancreas

New collaboration aims to develop novel generation artificial pancreas

Debiotech SA, the ARTORG Center for Biomedical Engineering Research of the University of Bern - and the Division of Endocrinology, Diabetes and Clinical Nutrition of the Bern University Hospital "Inselspital" are proud to announce the start of an exclusive collaboration to develop a novel generation artificial pancreas. [More]

Impax releases generic version of dutasteride capsules, 0.5 mg

Impax Laboratories, Inc. today announced that on November 20, the Company's development and manufacturing partner received final approval by the U.S. Food and Drug Administration for a generic version of dutasteride capsules, 0.5 mg. [More]
New insulin pill shows promise as novel form of therapy for diabetes

New insulin pill shows promise as novel form of therapy for diabetes

An insulin pill being developed by researchers at UC Santa Barbara may in the near future give another blood sugar management option to those who suffer from diabetes. The novel drug delivery technology may also apply to a wide spectrum of other therapies. [More]
Researchers reveal how charged gold nanoparticles influence structure of DNA and RNA

Researchers reveal how charged gold nanoparticles influence structure of DNA and RNA

Researchers at North Carolina State University have used computational modelling to shed light on precisely how charged gold nanoparticles influence the structure of DNA and RNA - which may lead to new techniques for manipulating these genetic materials. [More]
Boston Children's Hospital selects Vijay G. Sankaran to receive Rising Star Award

Boston Children's Hospital selects Vijay G. Sankaran to receive Rising Star Award

Saluting his spectacular track record to date of innovative research on red blood cell disorders and his future promise as a physician/scientist, Boston Children's Hospital has selected Vijay G. Sankaran, MD, PhD, of Dana-Farber/Boston Children's Cancer and Blood Disorders Center to receive the Rising Star Award at the hospital's third annual Global Pediatric Innovation Summit, Taking on Tomorrow (#PedInno15). [More]
Oasmia Pharmaceutical’s Paclical is bioequivalent of Celgene’s Abraxane in treatment of women with metastatic breast cancer

Oasmia Pharmaceutical’s Paclical is bioequivalent of Celgene’s Abraxane in treatment of women with metastatic breast cancer

Oasmia Pharmaceutical AB, a developer of a new generation of drugs within human and veterinary oncology, confirmed the previously published findings from a head-to-head comparison study of its lead human cancer product Paclical and Celgene’s Abraxane, demonstrated superimposable paclitaxel PK profiles. The study was conducted in women with metastatic breast cancer. [More]
Oasmia Pharmaceutical’s Paclical is bioequivalent of Celgene’s Abraxane in treatment of women with metastatic breast cancer

Oasmia Pharmaceutical’s Paclical is bioequivalent of Celgene’s Abraxane in treatment of women with metastatic breast cancer

Oasmia Pharmaceutical AB, a developer of a new generation of drugs within human and veterinary oncology, confirmed today the previously published findings from a head-to-head comparison study of its lead human cancer product Paclical and Celgene’s Abraxane, demonstrated superimposable paclitaxel PK profiles. The study was conducted in women with metastatic breast cancer. [More]
Advertisement
Advertisement